Despite showing good effects during the initial years of the COVID-19 pandemic, the use of anti-SARS-CoV-2 mAbs for the treatment of COVID-19 is no longer recommended, since amubarvimab/romlusevimab is no longer in clinical development due to its lack of activity against the current circulating variants and the high mutation rate that these variants present in the S protein [88]. Here, PROS1 is linked to COVID-19.